# Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

> **NCT07223632** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Charcot Marie Tooth Disease (CMT)
- Neuromuscular Diseases (NMD)

## Interventions

- **DRUG:** VCA-894A

## Key facts

- **NCT ID:** NCT07223632
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07223632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07223632, "Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07223632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*